Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
June 1, 2024Journal of Clinical Oncology

Predictors of good outcomes in patients with hepatocellular carcinoma (HCC) treated with transarterial radioembolization (TARE).

View Full Paper
Ask AI
Bookmark
Share

Authors

PDParthib DasSPSamuel PaulEMEric Min

Discussion

Loading...

Member takes

Overview

Key Points

Key points are not available for this paper at this time.

Cite This Study

Das et al. (2024) studied this question.

synapsesocial.com/papers/68e66eeab6db6435875f95d8https://doi.org/10.1200/jco.2024.42.16_suppl.e16219
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Post-TARE Survival Outcomes in Hepatocellular Carcinoma: Influence of Pre-TARE Immunotherapy and Targeted Therapy in a Real-World Cohort2026
  2. 2Predictors of outcome of transarterial locoregional therapies in unresectable hepatocellular carcinoma: a multicenter analysis2026
  3. 3Prognostic Value of Liver Biomarkers in Hepatocellular Carcinoma Patients Undergoing Yttrium 90 Transarterial Radioembolization (TARE): A Retrospective Pilot Study2024 · 3 citations
  4. 4Prognostic Value of Liver Function and Tumor Burden Scores in Patients with HCC After Transarterial Radioembolization – Retrospective Single Center Analysis2026
  5. 5Outcome of transarterial radioembolization in patients with hepatocellular carcinoma as a first-line interventional therapy and after a previous transarterial chemoembolization2024 · 5 citations